Developing Potential Treatments for a Variety of Tumor Types

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called REOLYSIN®, for the treatment of solid tumors and hematological malignancies. REOLYSIN® is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.

  • Defined registration pathway in metastatic breast cancer (mBC) allowing for rapid initiation of a single phase 3 trial required for approval
  • Leverage innate and adaptive immune mechanisms of REOLYSIN® in studies with checkpoint inhibitors as well as targeted and immunomodulatory (IMiD) combinations to explore new treatment applications

Collaborating for a Better Future

Oncolytics will grow via collaborative programs and studies and relationships with other biopharmaceutical companies. Our first collaboration with Myeloma UK and Celgene is a phase 1b study of REOLYSIN combined with Imnovid®/Revlimid® as a treatment for relapsing myeloma patients. We also recently announced a regional partnership with Adlai Nortye to develop REOLYSIN® for metastatic breast cancer. Oncolytics continues to investigate further collaboration opportunities with checkpoint inhibitors and immunomodulatory drugs that will help us to advance REOLYSIN in the adjuvant setting

REOLYSIN Manufacturing

REOLYSIN® is currently being manufactured at commercial scale in its final formulation under a commercial supply agreement with MilliporeSigma.